News stories about Veracyte (NASDAQ:VCYT) have trended positive recently, Accern reports. Accern scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Veracyte earned a coverage optimism score of 0.26 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.6162011406005 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Zacks: Analysts Anticipate Veracyte (VCYT) Will Announce Quarterly Sales of $18.32 Million (americanbankingnews.com)
- Biocept (BIOC) vs. Veracyte (VCYT) Head to Head Contrast (americanbankingnews.com)
- Veracyte (VCYT) versus The Competition Financial Comparison (americanbankingnews.com)
- Zacks: Brokerages Anticipate Veracyte (VCYT) to Post -$0.25 EPS (americanbankingnews.com)
- Veracyte (VCYT) Downgraded to Neutral at Piper Jaffray (americanbankingnews.com)
VCYT stock traded down $0.08 during midday trading on Thursday, hitting $5.74. The stock had a trading volume of 64,509 shares, compared to its average volume of 106,489. The stock has a market capitalization of $197.51, a P/E ratio of -6.31 and a beta of 1.62. The company has a debt-to-equity ratio of 0.68, a quick ratio of 4.04 and a current ratio of 4.49. Veracyte has a 12-month low of $5.23 and a 12-month high of $9.80.
A number of brokerages have recently weighed in on VCYT. Zacks Investment Research cut shares of Veracyte from a “hold” rating to a “sell” rating in a research note on Tuesday, March 6th. Piper Jaffray reaffirmed a “hold” rating and issued a $5.40 target price on shares of Veracyte in a research note on Thursday, March 1st. Finally, ValuEngine cut shares of Veracyte from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Two analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $10.78.
COPYRIGHT VIOLATION WARNING: This piece was published by BBNS and is the sole property of of BBNS. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://baseballnewssource.com/2018/04/06/veracyte-vcyt-receives-daily-media-impact-score-of-0-26/2029239.html.
Veracyte Company Profile
Veracyte, Inc operates as a genomic diagnostics company in the United States. The company uses genomic technology to resolve diagnostic uncertainty. It offers Afirma Thyroid FNA Analysis solution; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.